AzTrials
AzTrials

Mental FatiguePhase 4NCT06460181

Impact of Astaxanthin on Cognition in Recreationally Active Females

A Phase 4 study testing Astaxanthin in people with Mental Fatigue, run by University of North Alabama at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

The purpose of this study is to examine the protentional that the antioxidant Astaxanthin has on mitigating cognitive decline following mental fatigue. Read more about this study

Who is it for?
Ages 18 to 39 years, women onlyHealthy volunteers can take part
Conditions the study is for
Mental Fatigue
What is being tested?
Astaxanthin
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
26 participants
Where
1 siteUnited States
Study dates
1 Aug 2024to 14 Dec 2024
Phase
Phase 4

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 39 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • The participant population will be healthy, recreationally active females between the ages of 18-39 without any medical conditions. To be deemed recreationally active, they must meet the World Health Organization minimum activity guidelines of completing at least 150 to 300 min moderate-intensity activity or 75-150 min of vigorous-intensity activity a week, plus muscle-strengthening activities 2 or more days a week.
  • Adult females with a stable body weight (± 5 lbs.) for 2 months
  • Adult females with a normal menstrual cycle
  • Adult females not on a low-carb, high-fat diet or intermittent fasting
  • Adult females who are not pregnant of actively attempting to become pregnant

Who cannot join

  • -

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of North Alabama

    Florence, Alabama, 35632

Other trials in United States

About this study

Official title: Astaxanthin Supplementation Preserves Cognitive Markers of Executive Function Following Mental Fatigue in Females

The purpose of this study is to examine the protentional that the antioxidant Astaxanthin has on mitigating cognitive decline following mental fatigue.

Read the detailed description

Dietary supplements are used in all levels of sports to impact various areas of athletic performance. Prolonged physical activity or cognitive engagement, which is a part of the competition, can increase mental fatigue (MF) such that the athlete begins to experience impaired decision-making skills and slower reaction times, resulting in a less-than-optimal athlete by the end of the competition. Thus, identifying interventions that may preserve an individual's ability to perform following a state of MF would interest individuals often engaged in competition or training.

Astaxanthin (AX) is a naturally occurring antioxidant typically found in marine species such as algae, salmon, trout, and shellfish. AX's unique structure may mitigate inflammation. Cognitively, AX can cross the blood-brain barrier to help support the mitochondria when metabolic or cognitive demands are increased. While there have been promising results in elderly individuals of AX's ability to mitigate reductions in cognitive performance when fatigued. However, investigations in younger, more active individuals are warranted. Therefore, the purpose of this study to examine the impact of four weeks of AX supplementation at 12 mg/day on various markers of cognitive performance following a mental fatiguing protocol in recreationally active females.

The cognitive methods are adapted from another previous study titled, "No Benefit of Ingesting a Low-Dose Ketone Monoester Supplement on Markers of Cognitive Performance in Females" (IRB#: 2023-009). This study is a double-blind between design. Supplementation will last four weeks with each subject will consume either 12 mg/day of AX or a matched placebo. The participants will report to the lab for four separate trials. There will be two cognitive trials before and after supplementation. A 4 week supplementation period will occur after trials 1 \& 2, followed by a repeat of these sessions for post-testing. We hypothesize that AX will mitigate cognitive detriments following mental fatigue. The significance of these results may extend to female athletes looking to enhance performance by protecting cognitive ability from declining after fatigue.

Cognitive Protocol: Participants will use software called SOMA NPT to complete a series of validated cognitive tasks that test different aspects of cognition. The cognitive battery of test that will be used includes a Psychomotor Vigilance Test (PVT; 5 min), Task Switching (3 min), and Incongruent Flaker (3 min). The task that will be used to induce mental fatigue is a Time-Loaded-Dual-Back task (TLDB; 15 min). A control video titled World Class Trains (15 min) has been validated to produce no emotional response. Each subject will complete a trial with the mental fatigue protocol and a control before supplementation.

Lipid Panel: A lipid panel to asses participants cholesterol and glucose levels will be taken both pre and post supplementation by using a capillary finger prick.

Conditions
Mental Fatigue
Being tested
Astaxanthin, Placebo
Medical subject headings
Mental Fatigue

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AstaxanthinDietary supplement

    Manufactured by AstaReal Inc

  • PlaceboDietary supplement

    Manufactured by AstaReal Inc

Study groups in NCT06460181
Study groupRoleWhat they receive
AstaxanthinActive comparatorAstaxanthin will be administered in a dosage of 12 mg/day orally by one soft gel capsule per day. the capsule consist of natural Astaxanthin and olive oil.
Receives: Dietary Supplement: Astaxanthin
PlaceboPlacebo comparatorThe placebo will be administered orally by one soft gel capsule per day. The placebo contains olive oil and is color, order, and taste matched to the Astaxanthin soft gels.
Receives: Dietary Supplement: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Reaction Time

    How quickly the participant reacts to a stimulus. Expressed in millaseconds. The lower the number, the faster the participants reacted to the given stimulus. All test were conducted on an iPad using the cognitive software SOMANPT.

    Measured: Pre supplementation and 4 weeks supplementation period.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Jun 2024
  2. Study start1 Aug 2024
  3. Primary completion1 Nov 2024
  4. Study completion14 Dec 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Model description
Groups will be randomized and parallel. They will not cross-over with each other.
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
26 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06460181
Sponsor's protocol ID
2024-021
Status last verified
Apr 2026
First submitted
28 May 2024
Last updated
26 May 2026
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in